Method for treating hepatitis C virus with omega interferon
View Patent ↗Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained release delivery system that is suitable for long-term administration. A principal advantage of the method is that responsiveness to treatment can be ascertained with short-term dosimetric techniques using one formulation of an interferon, which permits the appropriate selection of a dose that is both effective and safe for long-term administration using the second formulation.
1. A method of treating hepatitis C virus (HCV) infection in a subject in need of such treatment, wherein the HCV infection exhibits primary or secondary resistance to treatment with alpha interferon, comprising
administering a therapeutically effective amount of omega interferon protein to the subject, the administering selected from the group consisting of:
(i) is at a controlled rate over time and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between 48 and 194 micrograms per week, between 23 and 388 micrograms per week, and between 23 and 623 micrograms per week, and
(ii) is by injection and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 1 and about 210 micrograms per week and between about 22.5 and about 360 micrograms per week.
2. The method of claim 1 , wherein the therapeutically effective amount of omega interferon is administered by injection.
3. The method of claim 2 , wherein the therapeutically effective amount of omega interferon is administered by one or more daily injections.
4. The method of claim 2 , wherein the therapeutically effective amount of omega interferon is administered by one or more injections given at selected dosing intervals.
5. The method of claim 4 , wherein the dosing interval comprises three injections per week.
6. The method of claim 2 , wherein the method of injection is selected from the group consisting of subcutaneous injection, intramuscular injection, and bolus intravenous injection.
7. The method of claim 6 , wherein the omega interferon is administered by subcutaneous injection.
8. The method of claim 1 , wherein the omega interferon is administered by infusion.
9. The method of claim 8 , wherein the method of infusion is chronic intravascular infusion.
10. The method of claim 1 , wherein the omega interferon is administered at a controlled rate over time.
11. The method of claim 10 , wherein a device is used to administer the omega interferon.
12. The method of claim 11 , wherein the device comprises a pump.
13. The method of claim 12 , wherein the device is either implanted in or external to the subject.
14. The method of claim 13 , wherein the device is implanted.
15. The method of claim 14 , wherein the device comprises an osmotic pump.
16. The method of claim 10 , wherein two or more implantable devices are used to administer the omega interferon.
17. The method of claim 1 , wherein the therapeutically effective amount of injected omega interferon is between about 1 and about 210 micrograms per week.
18. The method of claim 1 , wherein the therapeutically effective amount of injected omega interferon is between about 22.5 and about 360 micrograms per week.
19. The method of claim 1 , wherein the therapeutically effective amount of omega interferon administered at a controlled rate over time is between 23 and 623 micrograms per week.
20. The method of claim 1 , wherein the omega interferon is a recombinant omega interferon.
21. The method of claim 1 , wherein the treatment with alpha interferon further comprises treatment with ribavirin.
22. A method of treating hepatitis C virus (HCV) infection in a subject in need of such treatment, wherein the HCV infection exhibits primary or secondary resistance to treatment with alpha interferon, comprising
administering a therapeutically effective amount of omega interferon protein to the subject, the administering selected from the group consisting of:
(i) is at a controlled rate over time and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between 48 and 194 micrograms per week, between 23 and 388 micrograms per week, and between 23 and 623 micrograms per week, and
(ii) is by injection and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 1 and about 210 micrograms per week and between about 22.5 and about 360 micrograms per week;
wherein the therapeutically effective amount of omega interferon protein is administered over at least about one month.